Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.36 +5.0%	$3.04	$2.07 ▼ $4.20	$103.07M	0.39	105,031 shs	181,718 shs
CBIO Crescent Biopharma	$13.14 +11.9%	$0.00	$11.06 ▼ $63.00	$229.61M	1.52	106,004 shs	222,371 shs
NERV Minerva Neurosciences	$2.11 +16.1%	$1.69	$1.15 ▼ $3.38	$12.68M	-0.34	22,569 shs	128,413 shs
SYBX Synlogic	$1.51 +14.4%	$1.19	$0.90 ▼ $1.88	$15.44M	0.55	19,068 shs	228,915 shs
ZYNE Zynerba Pharmaceuticals	$1.30	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	N/A

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+5.00%	+6.67%	-10.40%	+23.53%	+4.35%
CBIO Crescent Biopharma	+11.93%	-11.16%	-98.29%	-98.29%	-98.29%
NERV Minerva Neurosciences	+16.07%	+22.95%	+18.26%	+31.56%	-37.16%
SYBX Synlogic	+14.39%	+21.77%	+24.79%	+42.45%	-3.21%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.9482 of 5 stars	3.6	3.0	0.0	0.0	2.5	3.3	0.0
CBIO Crescent Biopharma	3.1964 of 5 stars	3.8	0.0	0.0	3.7	2.8	1.7	0.6
NERV Minerva Neurosciences	4.226 of 5 stars	3.0	5.0	0.0	4.6	2.0	0.0	1.3
SYBX Synlogic	1.1518 of 5 stars	0.0	3.0	0.0	0.0	3.3	1.7	0.6
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	167.86% Upside
CBIO Crescent Biopharma	3.50	Strong Buy	$25.67	95.33% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	137.53% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NERV, ZYNE, SYBX, ANIX, and CBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	515.36	N/A	N/A	$0.59 per share	5.69
CBIO Crescent Biopharma	$10K	25,688.70	N/A	N/A	$8.24 per share	1.59
NERV Minerva Neurosciences	N/A	N/A	$0.24 per share	8.68	($3.67) per share	N/A
SYBX Synlogic	$10K	1,766.70	N/A	N/A	$1.09 per share	1.39
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
CBIO Crescent Biopharma	-$37.88M	-$46.00	N/A	N/A	N/A	N/A	-293.92%	-206.20%	N/A
NERV Minerva Neurosciences	$1.44M	$0.82	2.57	N/A	N/A	N/A	-20.68%	15.73%	8/5/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	10.91%	7.47%	8/6/2025 (Estimated)
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest NERV, ZYNE, SYBX, ANIX, and CBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	SYBX Synlogic	-$0.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	NERV Minerva Neurosciences	-$0.95	N/A	N/A	N/A	N/A	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/13/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	-$0.50	+$0.57	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
CBIO Crescent Biopharma	N/A	2.29	2.29
NERV Minerva Neurosciences	N/A	9.21	9.21
SYBX Synlogic	N/A	3.68	3.68
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
CBIO Crescent Biopharma	75.19%
NERV Minerva Neurosciences	34.56%
SYBX Synlogic	63.40%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
CBIO Crescent Biopharma	4.00%
NERV Minerva Neurosciences	8.60%
SYBX Synlogic	3.02%
ZYNE Zynerba Pharmaceuticals	13.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
NERV Minerva Neurosciences	9	N/A	N/A	Not Optionable
SYBX Synlogic	80	11.70 million	11.34 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

NERV, ZYNE, SYBX, ANIX, and CBIO Headlines

Recent News About These Companies

22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)

June 25, 2025 | globenewswire.com

Harmony Biosciences: If It Ain't Broke

June 5, 2025 | seekingalpha.com

US Penny Stocks To Watch In October 2024

October 28, 2024 | uk.finance.yahoo.com

Discover 3 US Penny Stocks With Market Caps Over $70M

October 24, 2024 | uk.finance.yahoo.com

Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight

October 22, 2024 | uk.finance.yahoo.com

GW Pharma's cannabis-derived epilepsy drug approved in EU

October 7, 2024 | pharmaphorum.comP

Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners

July 31, 2024 | globenewswire.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 31, 2023 | finance.yahoo.com

Why Shares of Harmony Bioscience Are Falling on Friday

October 13, 2023 | fool.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | markets.businessinsider.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 11, 2023 | finance.yahoo.com

H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)

October 10, 2023 | knoxdaily.comK

Analysts: ZYNE stock price target of $1.25 in 12 months

October 5, 2023 | knoxdaily.comK

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

October 4, 2023 | finance.yahoo.com

Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)

October 2, 2023 | knoxdaily.comK

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

September 29, 2023 | finance.yahoo.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 27, 2023 | bizjournals.com

Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise

September 25, 2023 | knoxdaily.comK

Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright

September 20, 2023 | knoxdaily.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, ZYNE, SYBX, ANIX, and CBIO Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.36 +0.16 (+5.00%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$3.44 +0.08 (+2.35%)

As of 04:05 AM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Crescent Biopharma NASDAQ:CBIO

$13.14 +1.40 (+11.93%)

As of 07/16/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Minerva Neurosciences NASDAQ:NERV

$2.10 +0.29 (+16.07%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.03 (-1.43%)

As of 04:04 AM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Synlogic NASDAQ:SYBX

$1.51 +0.19 (+14.39%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.54 +0.02 (+1.66%)

As of 06:27 AM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time